Martin Little - Concepedia

Author

Martin Little

University of Oxford ORCID

Also Known As

Darragh Duffy, Little M, M Little, M P Little, M. Little, Martin Little

Publications

384

Citations

H-Index

Concepts

All Affiliations

University of Oxford Oxford University Hospitals NHS Trust University Hospital Southampton NHS Foundation Trust University College London St James's University Hospital

About

Martin Little is an author at University of Oxford specializing in oncology, cancer therapeutics, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	38
2	Pharmacology	2	2	38
3	Education	1	1	13
4	Health Sciences	1	1	13
5	Obstetrics	1	1	17

Martin Little

Publications

269

Citations

H-Index

Page 1

	Year	Citations
Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study Lennard Y. W. Lee, Thomas Starkey, Maria C. Ionescu, The Lancet Oncology	2022	93
COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study Lennard Y. W. Lee, Maria C. Ionescu, Thomas Starkey, European Journal of Cancer	2022	63
Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer Lennard Y. W. Lee, Michaël Tilby, Thomas Starkey, JAMA Oncology	2022	29
Abstract CT143: Phase I study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions in <i>KRAS</i> mutant cancers Rajiv Shinde, Angelika Terbuch, Martin Little, Cancer Research PharmacotherapyTumor BiologyMolecular PharmacologyTranslational MedicineExpansion Cohorts	2020	21
A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP) Thomas Starkey, Maria C. Ionescu, Michaël Tilby, Scientific Reports	2023	20
725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer Susana Banerjee, Rafael Grochot, R. Shinde, Annals of Oncology MedicinePharmacologyGynecologyFak Inhibitor DefactinibAnti-cancer Agent	2021	17
Helping Families Change Martin Little Adoption & Fostering Families ChangeFamily SystemsFamily InvolvementCommunity EngagementSociology	1981	13
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade Gusztav Milotay, Martin Little, Robert Watson, Nature Medicine	2025	13

Page 1